Altimmune Form 3 / Andrew Shutterly ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Shutterly Andrew

(Last)

(First)

(Middle)

C/O ALTIMMUNE, INC.

910 CLOPPER ROAD, SUITE 201S

(Street)

GAITHERSBURG

20878

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/26/2024

3. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
See Remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value $0.0001	10,113	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	03/17/2032	Common Stock, par value $0.0001	20,000	7.05	D
Stock Option (Right to Buy)	⁽²⁾	01/30/2033	Common Stock, par value $0.0001	25,000	12.88	D
Stock Option (Right to Buy)	⁽³⁾	05/22/2033	Common Stock, par value $0.0001	15,000	4.48	D
Stock Option (Right to Buy)	⁽⁴⁾	01/25/2034	Common Stock, par value $0.0001	12,000	9.28	D
Restricted Stock Units	⁽⁵⁾	⁽⁵⁾	Common Stock, par value $0.0001	11,250	0.00	D
Restricted Stock Units	⁽⁶⁾	⁽⁶⁾	Common Stock, par value $0.0001	3,000	0.00	D

Explanation of Responses:

1. Twenty-five percent of the shares underlying the option became vested and exercisable on March 17, 2023 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following March 17, 2023, subject to the reporting person's continued service through the applicable vesting date.

2. Twenty-five percent of the shares underlying the option became vested and exercisable on January 30, 2024 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 30, 2024, subject to the reporting person's continued service through the applicable vesting date.

3. Twenty-five percent of the shares underlying the option became vested and exercisable on May 22, 2024 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following May 22, 2024, subject to the reporting person's continued service through the applicable vesting date.

4. Twenty-five percent of the shares underlying the option become vested and exercisable on January 25, 2025 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 25, 2025, subject to the reporting person's continued service through the applicable vesting date.

5. The RSUs will vest in equal annual installments of 3,750 shares on January 30, 2025, January 30, 2026 and January 30, 2027, subject to the reporting person's continued service through the applicable date, and have no expiration date.

6. The RSUs become vested and exercisable over four 4 years with 25% of the shares vesting on January 25, 2025, with the remainder vesting in equal annual installments for the following three years, subject to the reporting person's continued service through the applicable date, and have no expiration date.

Remarks:

Acting Chief Financial Officer. Exhibit 24 - Power of Attorney.

	/s/ Vipin K. Garg, as Attorney-in-Fact	07/01/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Altimmune (ALT) Form 3Altimmune / Andrew Shutterly ownership change